A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors

MYCN drives aggressive behavior and refractoriness to chemotherapy, in several tumors. Since MYCN inactivation in clinical settings is not achievable, alternative vulnerabilities of MYCN-driven tumors need to be explored to identify more effective and less toxic therapies. We previously demonstrated...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Giulio, Stefano, Colicchia, Valeria, Pastorino, Fabio, Pedretti, Flaminia, Fabretti, Francesca, Nicolis di Robilant, Vittoria, Ramponi, Valentina, Scafetta, Giorgia, Moretti, Marta, Licursi, Valerio, Belardinilli, Francesca, Peruzzi, Giovanna, Infante, Paola, Goffredo, Bianca Maria, Coppa, Anna, Canettieri, Gianluca, Bartolazzi, Armando, Ponzoni, Mirco, Giannini, Giuseppe, Petroni, Marialaura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553625/
https://www.ncbi.nlm.nih.gov/pubmed/34508175
http://dx.doi.org/10.1038/s41388-021-02003-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553625/
https://www.ncbi.nlm.nih.gov/pubmed/34508175
http://dx.doi.org/10.1038/s41388-021-02003-0

Ejemplares similares